Ad
related to: ATAI
Search results
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's Why
Zacks via Yahoo Finance· 6 months agoatai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects,...
Retail investors account for 59% of Atai Life Sciences N.V.'s (NASDAQ:ATAI) ownership, while...
Simply Wall St. via Yahoo Finance· 12 months agoKey Insights Significant control over Atai Life Sciences by retail investors implies that the...
Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV
GuruFocus.com via Yahoo Finance· 8 months agoOn September 13, 2023, Florian Brand, See Remarks at ATAI Life Sciences NV (NASDAQ:ATAI), made a...
Why Atai Life Sciences Stock Stormed Higher This Week
Motley Fool· 1 year agoAtai Life Sciences (NASDAQ: ATAI), a small-cap drugmaker developing psychedelic-based treatments for...
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 8, 2022 – Today, Zacks Investment Ideas feature...
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around...
Zacks via Yahoo Finance· 8 months agoatai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies...
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Motley Fool· 1 year agoWith its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its...
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 1 month agoAtai Life Sciences (NASDAQ:ATAI) Full Year 2023 Results Key Financial Results Net loss: US$40.2m...
The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a...
Business Insider via Yahoo News· 1 year agoA doctor prepares to give intravenous ketamine at a clinic in Palo Alto, California in 2019.Yalonda...
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
Benzinga via Yahoo Finance· 1 year agoHC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ: ATAI) from $50 to $20 to...